Loading provider…
Loading provider…
Medical Oncology Physician in Nashville, TN
NPI: 1427074210Primary Practice Location
TRISTAR SKYLINE MEDICAL CENTER
500 Hospital Dr, Madison, TN
Primary Employer
Nashville Oncology Associates, PC
tnoncology.com
HQ Phone
Get M.D. David's Phone Numberphone_androidMobile
Get M.D. David's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardTN State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 116 | 256 |
| 2 | 80053Blood test, comprehensive group of blood chemicals | 114 | 535 |
| 3 | 85025Complete blood cell count (red cells, white blood cell, platelets), automated test | 112 | 537 |
| 4 | 36415Insertion of needle into vein for collection of blood sample | 95 | 385 |
| 5 | 96413Infusion of chemotherapy into a vein up to 1 hour | 94 | 279 |
Authors: Barlesi, Fabrice, Vansteenkiste, Johan, Spigel, David, Ishii, Hidenobu, Garassino, Marina, de Marinis, Filippo, Özgüroğlu, Mustafa, Szczesna, Aleksandra, Polychronis, Andreas, Uslu, Ruchan, Krzakowski, Maciej, Lee, Jong-Seok, Calabrò, Luana, Arén Frontera, Osvaldo, Ellers-Lenz, Barbara, Bajars, Marcis, Ruisi, Mary, Park, Keunchil
Journal: Lancet Oncol
Publication Date: 2018-09-24
Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics.
Authors: Erika Hamilton
Journal: JCO Precis Oncol
Lead Sponsor: Tango Therapeutics, Inc.
Intervention / Treatment: DRUG: TNG908
Lead Sponsor: GlaxoSmithKline
Collaborators: iTeos Belgium SA
Intervention / Treatment: DRUG: Docetaxel, DRUG: Ipilimumab, DRUG: Dostarlimab, DRUG: GSK6097608, DRUG: Feladilimab, DRUG: GSK4428859A
Lead Sponsor: EMD Serono Research & Development Institute, Inc.
Collaborators: Merck KGaA, Darmstadt, Germany
Intervention / Treatment: DRUG: Pembrolizumab, DRUG: M7824